Shandong Realcan Pharmaceutical Co Ltd (SHE:002589) — Market Cap & Net Worth
Market Cap & Net Worth: Shandong Realcan Pharmaceutical Co Ltd (002589)
Shandong Realcan Pharmaceutical Co Ltd (SHE:002589) has a market capitalization of $596.71 Million (CN¥4.08 Billion) as of August 1, 2026. Listed on the SHE stock exchange, this China-based company holds position #11068 globally and #2986 in its home market, demonstrating a 1.50% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shandong Realcan Pharmaceutical Co Ltd's stock price CN¥2.71 by its total outstanding shares 1504710471 (1.50 Billion). See 002589 capital expenditure intensity to understand how much of operating cash flow is reinvested back into capital assets.
Shandong Realcan Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Shandong Realcan Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $3.34 Billion to $596.71 Million (-14.37% CAGR).
Shandong Realcan Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shandong Realcan Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.10x
Shandong Realcan Pharmaceutical Co Ltd's market cap is 0.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
44.12x
Shandong Realcan Pharmaceutical Co Ltd's market cap is 44.12 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.02 Billion | $15.62 Billion | $590.76 Million | 0.19x | 5.12x |
| 2017 | $2.89 Billion | $23.29 Billion | $1.01 Billion | 0.12x | 2.86x |
| 2018 | $1.50 Billion | $33.92 Billion | $771.18 Million | 0.04x | 1.95x |
| 2019 | $1.67 Billion | $35.26 Billion | -$927.80 Million | 0.05x | N/A |
| 2020 | $1.14 Billion | $27.23 Billion | $261.30 Million | 0.04x | 4.35x |
| 2021 | $857.19 Million | $21.06 Billion | $131.18 Million | 0.04x | 6.53x |
| 2022 | $900.36 Million | $12.31 Billion | -$1.83 Billion | 0.07x | N/A |
| 2023 | $714.62 Million | $8.03 Billion | $20.32 Million | 0.09x | 35.17x |
| 2024 | $653.95 Million | $7.97 Billion | $20.62 Million | 0.08x | 31.71x |
| 2025 | $709.00 Million | $7.30 Billion | $16.07 Million | 0.10x | 44.12x |
Competitor Companies of 002589 by Market Capitalization
Companies near Shandong Realcan Pharmaceutical Co Ltd in the global market cap rankings as of August 1, 2026.
Key companies related to Shandong Realcan Pharmaceutical Co Ltd by market ranking:
- McKesson Corporation (NYSE:MCK): Ranked #273 globally with a market cap of $94.62 Billion USD.
- Cencora Inc. (NYSE:COR): Ranked #525 globally with a market cap of $50.53 Billion USD.
- Cardinal Health Inc (NYSE:CAH): Ranked #623 globally with a market cap of $43.01 Billion USD.
- Sigma Healthcare Ltd (AU:SIG): Ranked #1088 globally with a market cap of $24.18 Billion USD ( AU$34.17 Billion AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #273 | McKesson Corporation | NYSE:MCK | $94.62 Billion | $865.51 |
| #525 | Cencora Inc. | NYSE:COR | $50.53 Billion | $312.23 |
| #623 | Cardinal Health Inc | NYSE:CAH | $43.01 Billion | $227.07 |
| #1088 | Sigma Healthcare Ltd | AU:SIG | $24.18 Billion | AU$2.96 |
Shandong Realcan Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Shandong Realcan Pharmaceutical Co Ltd's market cap moved from $3.34 Billion to $ 596.71 Million, with a yearly change of -14.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥596.71 Million | -15.84% |
| 2025 | CN¥709.00 Million | +8.42% |
| 2024 | CN¥653.95 Million | -8.49% |
| 2023 | CN¥714.62 Million | -20.63% |
| 2022 | CN¥900.36 Million | +5.04% |
| 2021 | CN¥857.19 Million | -24.56% |
| 2020 | CN¥1.14 Billion | -31.99% |
| 2019 | CN¥1.67 Billion | +11.09% |
| 2018 | CN¥1.50 Billion | -47.92% |
| 2017 | CN¥2.89 Billion | -4.44% |
| 2016 | CN¥3.02 Billion | -9.50% |
| 2015 | CN¥3.34 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 31st, 2026 the market cap of Shandong Realcan Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $596.71 Million USD |
| MoneyControl | $596.71 Million USD |
| MarketWatch | $596.71 Million USD |
| marketcap.company | $596.71 Million USD |
| Reuters | $596.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shandong Realcan Pharmaceutical Co Ltd
Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institutions in China. It operates through the Drug and Equipment Distribution, In Vitro Diagnostics, Pharmaceutical Logistics, Traditional Chinese Medicine, and Microbiome Medicine segments. The company engages in the processing, manufacture, sale, and wholesale of Chinese medicinal materi… Read more